These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38888389)

  • 1. [Risk minimalisation measures for medications; are they incorporated in Dutch clinical guidelines?].
    Grupstra RJ; Siiskonen SJ; Gardarsdottir H
    Ned Tijdschr Geneeskd; 2024 Jun; 168():. PubMed ID: 38888389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
    Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
    Drug Saf; 2021 Feb; 44(2):193-209. PubMed ID: 33125664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe.
    Madison T; Donner B; Mutter R; Mingrino R; Alvaro G
    Pharmaceut Med; 2019 Oct; 33(5):395-406. PubMed ID: 31933233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk-minimization measures.
    Salem L; Malouvier A; Blatchford J; Rivero-Ferrer E; Deltour N; Jacquot E
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1470-1479. PubMed ID: 31486198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodological approach to inter "guideline" variability in the management of bipolar disorders].
    Samalin L; Llorca PM
    Encephale; 2012 Apr; 38(2):126-32. PubMed ID: 22516270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the quantitative effectiveness of risk management measures (RMM) in the workplace.
    Goede H; Ge C; Fransman W
    Ann Work Expo Health; 2024 Jun; 68(5):495-509. PubMed ID: 38563681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures.
    Jacquot E; Collin E; Ladner A; Tormos A; Hamm L; Perez-Gutthann S; Gutierrez L; Chirila C; Deltour N
    Pharmaceut Med; 2019 Aug; 33(4):311-319. PubMed ID: 31933191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are drug safety measures harmonized? A real-world evidence from three regulatory authorities.
    Alelayan S; Al-Sheikh L; Almotawa R; Alkofide H; Alshammari T
    Saudi Pharm J; 2024 Mar; 32(3):101963. PubMed ID: 38328792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK.
    Ehlken B; Nishikawa C; Kaplan S; Dresco I; Granados D; Toussi M
    Curr Med Res Opin; 2022 Mar; 38(3):461-468. PubMed ID: 34931552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of risk minimisation measures for valproate: a drug utilisation study in Europe, analysis of data from Spain.
    Ehlken B; Stevanovic I; Kaplan S; Dresco I; Granados D; Toussi M
    Rev Neurol; 2021 Dec; 73(11):373-382. PubMed ID: 34826330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatologists' adherence to the guideline of the Dutch Society of Dermatology and Venereology with respect to the treatment with methotrexate for severe chronic plaque psoriasis: results from a Dutch survey.
    Berends MA; de Jong EM; van de Kerkhof PC; Gerritsen MJ
    Dermatology; 2007; 215(1):45-52. PubMed ID: 17587839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
    Farcas A; Huruba M; Mogosan C
    Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a questionnaire to identify perceived barriers for implementing the Dutch physical therapy COPD clinical practice guideline.
    van der Wees PJ; Zagers CA; de Die SE; Hendriks EJ; Nijhuis-van der Sanden MW; de Bie RA
    BMC Health Serv Res; 2013 May; 13():159. PubMed ID: 23631555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review.
    Bennett WL; Odelola OA; Wilson LM; Bolen S; Selvaraj S; Robinson KA; Bass EB; Puhan MA
    Ann Intern Med; 2012 Jan; 156(1 Pt 1):27-36. PubMed ID: 22213492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate preparations for agitation in dementia.
    Baillon SF; Narayana U; Luxenberg JS; Clifton AV
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD003945. PubMed ID: 30293233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
    Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
    Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once-weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour.
    Lysen T; Karimi L; Wang M; Singh S; Toussi M
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5692. PubMed ID: 37661305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.